Stockscreener 앱 받기
2.83
3.41%
-0.10
시간 외 거래:
2.83
전일 마감가:
$2.93
열려 있는:
$2.95
하루 거래량:
40,946
Relative Volume:
0.37
시가총액:
$17.88M
수익:
-
순이익/손실:
$-11.46M
주가수익비율:
-0.2021
EPS:
-14
순현금흐름:
$-24.56M
1주 성능:
+8.43%
1개월 성능:
+14.11%
6개월 성능:
+9.69%
1년 성능:
-75.39%
1일 변동 폭
$2.80
$2.9899
1주일 범위
$2.6101
$2.9899
52주 변동 폭
$1.20
$17.75
에바종 바이오테크 Stock (EVAX) Company Profile
EVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
2.83 | 17.88M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
에바종 바이오테크 Stock (EVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-02 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | 개시 | H.C. Wainwright | Buy |
에바종 바이오테크 주식(EVAX)의 최신 뉴스
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
Evaxion reports progress in cancer vaccine trial, extends cash runway - Investing.com
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Evaxion secures Nasdaq listing with equity boost - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
에바종 바이오테크 (EVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):